152 related articles for article (PubMed ID: 18513885)
1. Prospective study of alternating chemoradiotherapy consisting of extended-field dynamic conformational radiotherapy and systemic chemotherapy using 5-FU and nedaplatin for patients in high-risk group with cervical carcinoma.
Kodaira T; Fuwa N; Nakanishi T; Tachibana H; Nakamura T; Tomita N; Nakahara R; Inokuchi H
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):251-8. PubMed ID: 18513885
[TBL] [Abstract][Full Text] [Related]
2. Single-institute phase I/II trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma.
Kodaira T; Fuwa N; Kamata M; Furutani K; Tachibana H; Yamazaki T
Anticancer Res; 2006; 26(1B):471-8. PubMed ID: 16739307
[TBL] [Abstract][Full Text] [Related]
3. High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.
Kim YS; Kim JH; Ahn SD; Lee SW; Shin SS; Nam JH; Kim YT; Kim YM; Kim JH; Choi EK
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1522-8. PubMed ID: 19231106
[TBL] [Abstract][Full Text] [Related]
4. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
[TBL] [Abstract][Full Text] [Related]
5. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Eifel PJ; Winter K; Morris M; Levenback C; Grigsby PW; Cooper J; Rotman M; Gershenson D; Mutch DG
J Clin Oncol; 2004 Mar; 22(5):872-80. PubMed ID: 14990643
[TBL] [Abstract][Full Text] [Related]
6. Cervical cancer: combined modality therapy.
Grigsby PW
Cancer J; 2001; 7 Suppl 1():S47-50. PubMed ID: 11504285
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer.
Kim YS; Shin SS; Nam JH; Kim YT; Kim YM; Kim JH; Choi EK
Gynecol Oncol; 2008 Jan; 108(1):195-200. PubMed ID: 17963825
[TBL] [Abstract][Full Text] [Related]
8. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemotherapy and hypofractionated twice-daily radiotherapy in cervical cancer patients with stage IIIB disease and bilateral parametrial involvement: a phase I-II study.
Viegas CM; Araujo CM; Dantas MA; Froimtchuk M; Oliveira JA; Marchiori E; Souhami L
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1154-9. PubMed ID: 15519787
[TBL] [Abstract][Full Text] [Related]
10. Intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil with concurrent radiation therapy for patients with high-risk uterine cervical cancer.
Kawase S; Okuda T; Ikeda M; Ishihara S; Itoh Y; Yanagawa S; Ishigaki T
Gynecol Oncol; 2006 Sep; 102(3):493-9. PubMed ID: 16478629
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients.
Chen MF; Tseng CJ; Tseng CC; Yu CY; Wu CT; Chen WC
Cancer J; 2008; 14(3):200-6. PubMed ID: 18536561
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of alternating chemoradiotherapy by conformal radiotherapy combined with intracavitary brachytherapy for high-risk cervical cancer.
Hirata K; Kodaira T; Tomita N; Ohshima Y; Ito J; Tachibana H; Nakanishi T; Fuwa N
Jpn J Clin Oncol; 2014 Jun; 44(6):556-63. PubMed ID: 24755546
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy with nedaplatin after radical hysterectomy in patients with stage IB and II cervical cancer.
Kobayashi Y; Ohara T; Wada Y; Okuda Y; Kondo H; Okuma Y; Suzuki N; Gomi H; Kiguchi K; Ishizuka B
J Obstet Gynaecol Res; 2009 Jun; 35(3):490-4. PubMed ID: 19527388
[TBL] [Abstract][Full Text] [Related]
14. Chemoradiation therapy using radiotherapy, systemic chemotherapy with 5-fluorouracil and nedaplatin, and intra-arterial infusion using carboplatin for locally advanced head and neck cancer - Phase II study.
Fuwa N; Kodaira T; Furutani K; Tachibana H; Nakamura T; Daimon T
Oral Oncol; 2007 Nov; 43(10):1014-20. PubMed ID: 17258494
[TBL] [Abstract][Full Text] [Related]
15. Dose escalation study of nedaplatin with 5-fluorouracil in combination with alternating radiotherapy in patients with head and neck cancer.
Fuwa N; Kodaira T; Tachibana H; Nakamura T; Daimon T
Jpn J Clin Oncol; 2007 Mar; 37(3):161-7. PubMed ID: 17332057
[TBL] [Abstract][Full Text] [Related]
16. Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: study of JROSG (Japan Radiation Oncology Study Group).
Sakata K; Sakurai H; Suzuki Y; Katoh S; Ohno T; Toita T; Kataoka M; Tanaka E; Kaneyasu Y; Uno T; Harima Y; Nakano T;
Acta Oncol; 2008; 47(3):434-41. PubMed ID: 18348003
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer.
Kim K; Chie EK; Wu HG; Ha SW; Kim JS; Kim IA; Lee HP
Gynecol Oncol; 2006 Jun; 101(3):398-402. PubMed ID: 16330087
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification for failure in patients with advanced cervical cancer after concurrent chemoradiotherapy: another way to optimise treatment results.
Liang JA; Chen SW; Chang WC; Hung YC; Yeh LS; Yang SN; Lin FJ
Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):683-90. PubMed ID: 18676129
[TBL] [Abstract][Full Text] [Related]
19. [Alternating chemoradiotherapy for oropharyngeal cancer].
Sasaoka M; Fuwa N; Matsumoto A; Kimura Y; Furutani K; Kamata M; Kodaira T; Morita K
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2217-21. PubMed ID: 11142165
[TBL] [Abstract][Full Text] [Related]
20. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors.
Mabuchi S; Morishige K; Isohashi F; Yoshioka Y; Takeda T; Yamamoto T; Yoshino K; Enomoto T; Inoue T; Kimura T
Gynecol Oncol; 2009 Dec; 115(3):482-7. PubMed ID: 19783286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
